Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) (ODIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00524368
Recruitment Status : Completed
First Posted : September 3, 2007
Results First Posted : September 22, 2010
Last Update Posted : February 15, 2013
Sponsor:
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland

Tracking Information
First Submitted Date  ICMJE August 30, 2007
First Posted Date  ICMJE September 3, 2007
Results First Submitted Date  ICMJE August 27, 2010
Results First Posted Date  ICMJE September 22, 2010
Last Update Posted Date February 15, 2013
Study Start Date  ICMJE October 2007
Actual Primary Completion Date August 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 12, 2013)
Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm [ Time Frame: 48 Weeks ]
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response. In all other cases, intermittent values were imputed with nonresponse. Resuppression after confirmed virologic failure was considered as failure in this algorithm.
Original Primary Outcome Measures  ICMJE
 (submitted: August 30, 2007)
Non-inferiority in virologic response, defined as a confirmed plasma viral load of < 50 HIV-1 RNA copies/mL at Week 48 (defined by time of loss of virologic response [TLOVR] algorithm), with DRV/rtv 800/100 mg daily versus DRV/rtv 600/100 mg twice daily.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 12, 2013)
  • Virologic Response at Week 48 (Viral Load Less Than 400 Copies/mL) [ Time Frame: 48 weeks ]
    Number of participants with confirmed plasma viral load less than 400 copies/mL at Week 48.
  • Change in log10 Viral Load From Baseline at Week 48 [ Time Frame: 48 weeks ]
  • Time to Reach First Virologic Response [ Time Frame: 48 weeks ]
    Time (in weeks) to achieve viral load less than 50 copies/mL by the participants.
  • Time to Loss of Virologic Response [ Time Frame: 48 weeks ]
    Time taken to lose the virologic response ie, plasma viral load less than 50 copies/mL by participants.
  • Time-averaged Difference (DAVG) of log10 Plasma Viral Load Over 48 Weeks [ Time Frame: 48 weeks ]
  • Change in CD4+ Cell Count From Baseline [ Time Frame: 48 Weeks ]
    CD4+ cell count was calculated using the Last Observation Carried Forward (LOCF) algorithm.
  • Change From Baseline in Total Functional Assessment of HIV Infection (FAHI) Score [ Time Frame: 48 weeks ]
    The FAHI is a 44-item questionnaire and incorporates 5 functional scales (physical well-being, emotional well-being/living with HIV, functional and global well-being, social well-being, and cognitive functioning). Each scale included several questions (all 5 scales include total 44 questions). For each question, participants gave a score of either 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit) and 4 (very much). Total FAHI imputed score is calculated by adding scores for each question. The range of total FAHI score is 0 to 176. Higher scores indicate worsening.
  • Percentage of Participants Adherent/Non-adherent to ARV as Determined by Modified Medication Adherence Self Report Inventory (M-MASRI) Questionnaire at Week 48 [ Time Frame: 48 weeks ]
    Self-reported adherence to the ARV medications was measured. The M-MASRI asks participants to report the number of doses taken, as well as the number of doses taken during the last 30 days prior to the study visit by means of a horizontal visual analogue scale (VAS) that generates a self-rated percentage of doses of all the ARV medications taken during the past 30 days.
  • Area Under the Curve From the Time of Study Medication Administration Upto 24 Hour Postdose (AUC24h) of DRV and Rtv [ Time Frame: 0 hour predose and 1 hour post dose measured at Weeks 4 and 24. Any time point measured at Weeks 8 and 48. ]
    Pharmacokinetic parameter AUC24h was assessed from the time of study medication administration upto 24 hour postdose. Population Pharmacokinetic Estimates of DRV and rtv were evaluated.
  • Predose Plasma Concentration (C0h) of DRV and Rtv. [ Time Frame: 0 hour predose and 1 hour post dose measured at Weeks 4 and 24. Any time point measured at Weeks 8 and 48 ]
    Pharmacokinetic parameter C0h was assessed. Population Pharmacokinetic Estimates of DRV and rtv were evaluated.
  • Number of Participants Developing Mutations at Endpoint [ Time Frame: 48 weeks ]
    Development of Mutations in Virologic Failures (Plasma Viral Load less than 50 Copies/mL) at endpoint.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 30, 2007)
Safety, tolerability, durability of effectiveness, change in viral load from baseline, percentage patients with confirmed plasma viral load < 50 HIV-1 RNA copies/mL, lipid effects,immunologic response, resistance characteristics, PK, Quality of Life, ...
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
Official Title  ICMJE A Randomized, Open-label Trial to Compare the Efficacy, Safety and Tolerability of DRV/Rtv (800mg/100mg) q.d Versus DRV/Rtv (600mg/100mg) b.i.d in Early Treatment-experienced HIV-1 Infected Subjects
Brief Summary The purpose of this study is to test if being treated with darunavir/ritonavir (DRV/rtv) 800/100 mg daily is as effective as being treated with DRV/rtv 600/100 mg twice daily, in early antiretroviral (ARV)-experienced patients when given along with selected optimized background regimen (OBR).
Detailed Description This is a randomized (the study medication is assigned by chance), open-label (all people know the identity of the intervention) study in which 590 patients will be randomly assigned to receive either DRV/rtv 800/100 mg daily or DRV/rtv 600/100 mg twice daily along with the selected OBR. An OBR will consist of at least 2 nucleoside reverse transcriptase inhibitors (NRTIs) selected by the investigator. The study will include a 4 week screening period, 48-weeks of treatment period and 4-weeks of follow-up. The study will also consists of extension phase after Week 48: in regions where DRV is not yet commercially available or reimbursed by the health care system, patients who complete the 48 weeks of treatment with DRV/rtv and who continue to benefit from this treatment, will have the opportunity to continue DRV treatment as a 600 mg twice daily dosage until DRV is reimbursed and available via the public and/or private health care system or until its development is discontinued. Safety evaluation will consists of adverse events (including specific toxicities), clinical laboratory tests, vital signs, electrocardiogram, physical and skin examination.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Human Immunodeficiency Virus - Type 1
Intervention  ICMJE
  • Drug: Darunavir (DRV)
    DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
    Other Name: TMC114
  • Drug: Ritonavir (rtv)
    DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
    Other Name: rtv
Study Arms  ICMJE
  • Experimental: DRV/rtv 800/100 mg once daily
    Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
    Interventions:
    • Drug: Darunavir (DRV)
    • Drug: Ritonavir (rtv)
  • Experimental: DRV/rtv 600/100 mg twice daily
    One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.
    Interventions:
    • Drug: Darunavir (DRV)
    • Drug: Ritonavir (rtv)
Publications * Lathouwers E, De La Rosa G, Van de Casteele T, Baeten B, Tomaka F, De Meyer S, Picchio G. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients. Antivir Ther. 2013;18(3):289-300. doi: 10.3851/IMP2569. Epub 2013 Apr 4.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 12, 2013)
590
Original Enrollment  ICMJE
 (submitted: August 30, 2007)
612
Actual Study Completion Date  ICMJE October 2011
Actual Primary Completion Date August 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with documented human immunodeficiency virus - Type 1 (HIV-1) infection
  • Patients with a viral load greater than 1,000 HIV-1 ribonucleic acid (RNA) copies/mL
  • Stable highly active antiretroviral therapy (HAART) regimen for at least 12 weeks at screening
  • In the investigator's opinion, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are not a valid treatment option, because of the patient's antiretroviral (ARV) treatment history, ARV resistance testing, medication-taking behavior, safety and tolerability concerns, or other patient-related factors
  • Prescreening or/and screening plasma HIV-1 RNA greater than 1,000 copies/mL on HAART regimen at screening

Exclusion Criteria:

  • Presence of any currently active conditions that fit the definition of the World Health Organization (WHO) Clinical Stage 4, with the following exceptions: stable cutaneous kaposi's sarcoma (ie, no internal organ involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the study time period, wasting syndrome
  • Patients for whom an investigational ARV is part of the current regimen, with the following exceptions if applicable (depending on local regulatory approval): tenofovir, emtricitabine
  • Previous or current use of enfuvirtide (ENF), tipranavir and/or DRV
  • Life expectancy of less than 12 months
  • Pregnant or breast-feeding females
  • Any active clinically significant disease (eg, tuberculosis [TB], cardiac dysfunction, pancreatitis, acute viral infections) or findings during screening of medical history or physical examination that, in the investigator's opinion, would compromise the patient's safety or outcome of the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Austria,   Brazil,   Chile,   France,   Germany,   Guatemala,   Hungary,   Malaysia,   Panama,   Puerto Rico,   Romania,   South Africa,   Spain,   Taiwan,   Thailand,   United Kingdom,   United States
Removed Location Countries Belgium,   Mexico,   Poland
 
Administrative Information
NCT Number  ICMJE NCT00524368
Other Study ID Numbers  ICMJE CR013783
TMC114-TiDP31-C229 ( Other Identifier: Tibotec Pharmaceuticals, Ireland )
2007-001939-61 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Tibotec Pharmaceuticals, Ireland
Study Sponsor  ICMJE Tibotec Pharmaceuticals, Ireland
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Tibotec Pharmaceuticals, Ireland Clinical Trial Tibotec Pharmaceuticals, Ireland
PRS Account Tibotec Pharmaceuticals, Ireland
Verification Date February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP